ライフサイエンスコーパス: adenosine diphosphate ribose

1 egy: a cyclic phosphodiesterase that acts on adenosine diphosphate-ribose 1"-2" cyclic phosphate (App

2 isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive

3 ribosyltransferases catalyze the transfer of adenosine diphosphate ribose (ADP-ribose) from nicotinam

4 brane protein that converts NAD primarily to adenosine diphosphate ribose (ADPR) and a small amount o

5 It metabolizes NAD(+) to adenosine diphosphate ribose (ADPR) and cyclic ADPR, reg

6 However, these enzymes also produce adenosine diphosphate ribose (ADPR) and nicotinic acid a

7 shows structural similarity to both TIR and adenosine diphosphate ribose (ADPR) cyclase.

8 where, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide aden

9 It is activated by intracellular adenosine diphosphate ribose (ADPR) through a diphosphor

10 ous substrates (e.g. lipopolysaccharides and adenosine diphosphate ribose (ADPr)) challenged this per

11 valent conjugation with the reaction product adenosine diphosphate ribose (ADPR).

12 this strategy should be applicable to cyclic adenosine diphosphate ribose and nicotinic acid adenine

13 PM2 channels were activated by intracellular adenosine diphosphate-ribose and blocked by flufenamic a

14 We identify a variant of cyclic adenosine diphosphate ribose as a biomarker of TIR enzym

15 f two potent Ca(2+) releasing agents: cyclic adenosine diphosphate ribose (cADPR) from nicotinamide a

16 of the calcium-mobilizing metabolite, cyclic adenosine diphosphate ribose (cADPR), from nicotinamide

17 We demonstrate that cyclic adenosine diphosphate ribose (cADPR), the product of CD3

18 osal mast cells through an IL-13-CD38-cyclic adenosine diphosphate ribose (cADPR)-dependent process.

19 e ribose (ADPR) and a small amount of cyclic adenosine diphosphate ribose (cADPR).

20 k incorporates the signaling molecule cyclic adenosine diphosphate ribose (cADPR).

21 ates the cytosolic signaling molecule cyclic adenosine diphosphate ribose (cADPR).

22 Blockade of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine-sensitive

23 sitol 1,4,5-trisphosphate (IP(3)) and cyclic adenosine diphosphate-ribose (cADPR) are second messenge

24 parks was increased by calmodulin and cyclic adenosine diphosphate-ribose (cADPR).

25 ng agents sphingosine-1-phosphate and cyclic adenosine diphosphate ribose exhibited weaker ABA-stimul

26 ial growth factor, 3-nitrotyrosine, and poly(adenosine diphosphate ribose) expression in lung tissue.

27 is a calcium-permeable channel activated by adenosine diphosphate ribose metabolites and oxidative s

28 ) resulting in the generation of polymers of adenosine diphosphate-ribose (PAR).

29 ROS), 3-nitrotyrosine (marker of RNS), poly(adenosine diphosphate-ribose) (PAR, marker of PARP activ

30 Recent approvals of polymeric adenosine diphosphate ribose (poly(ADP-ribose) polymeras

31 of caspase-2 and caspase-3, cleavage of poly(adenosine diphosphate-ribose) (poly(ADP-ribose)) polymer

32 accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase (PARP) cleavage

33 tibody that blocks angiogenesis) and/or poly-adenosine diphosphate ribose polymerase (PARP) inhibitor

34 age during transplantation can activate poly-adenosine diphosphate ribose polymerase (PARP) resulting

35 However, olaparib, an oral poly-adenosine diphosphate ribose polymerase inhibitor, is es

36 rgery, radiation, and therapies such as poly-adenosine diphosphate ribose polymerase inhibitors for B

37 on stress, a defect accentuated by poly-ADP (adenosine diphosphate) ribose polymerase inhibitors.

38 Similarly, the NAD-dependent poly(adenosine diphosphate)ribose polymerase 1 (PARP1) may af

39 rial dysfunction, caspase cleavage, and poly adenosine diphosphate-ribose polymerase (PARP) degradati

40 ing for imbalances in subsequent use of poly adenosine diphosphate-ribose polymerase inhibitors and o

41 by caspase-8, -9, and -3 and PARP (poly-ADP [adenosine diphosphate]-ribose polymerase) cleavage and d

42 Poly(adenosine diphosphate ribose) polymerase (PARP) has emer

43 Methods: We used a radiolabled poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

44 st cancer (TNBC) cells are sensitive to poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

45 NBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

46 Caspase activity, measured by poly (adenosine diphosphate ribose) polymerase (PARP) proteoly

47 stigated PARPi-FL, an exogenous nuclear poly(adenosine diphosphate ribose) polymerase (PARP1)-targete

48 o human skin indicated that PARPi-FL, a poly(adenosine diphosphate ribose) polymerase 1 (PARP1) inhib

49 p53 interacting with and delivering the poly(adenosine diphosphate ribose) polymerase 1 (PARP1)/Ku70

50 wn or putative radiosensitizers such as poly(adenosine diphosphate ribose) polymerase and mammalian-t

51 ired IHHs displayed caspase activation, poly(adenosine diphosphate ribose) polymerase cleavage, and a

52 ngs (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, rad

53 In cells deficient in the telomeric poly(adenosine diphosphate ribose) polymerase tankyrase 1, si

54 noblots demonstrated adaphostin induced poly(adenosine diphosphate-ribose) polymerase (PARP) cleavage

55 ected by caspases-3 and -8 cleavage and poly(adenosine diphosphate-ribose) polymerase (PARP) degradat

56 The poly-(adenosine diphosphate-ribose) polymerase (PARP) family o

57 a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

58 repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

59 t for patients who have progressed on a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

60 ient epithelial ovarian cancer (EOC) to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

61 Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

62 ated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

63 Few prospective studies have compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

64 patients, 13 (33.3%) were eligible for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

65 1/2 alterations are eligible to receive poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

66 Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

67 ding DNA fragmentation and cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP), as well

68 ankyrins and to the catalytic domain of poly(adenosine diphosphate-ribose) polymerase (PARP), was ide

69 gen species (RNS) and the activation of poly(adenosine diphosphate-ribose) polymerase (PARP).

70 f caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).

71 the human bax promoter and found that poly (adenosine diphosphate-ribose) polymerase 1 recruited the

72 mitochondrial membrane potential, and poly (adenosine diphosphate-ribose) polymerase cleavage.

73 C-alpha, phospho-PKC-beta1, and cleaved poly(adenosine diphosphate-ribose) polymerase in post-CP/Rep

74 HR) as measured by hypersensitivity to poly (adenosine diphosphate-ribose) polymerase inhibition and

75 high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor 3-ami

76 e another complementary determinant of poly (adenosine diphosphate-ribose) polymerase inhibitor effic

77 onsistent with the association between poly (adenosine diphosphate-ribose) polymerase inhibitor effic

78 of 1% to 3% of patients treated with a poly(adenosine diphosphate-ribose) polymerase inhibitor for h

79 asibility and toxicity of combining the poly(adenosine diphosphate-ribose) polymerase inhibitor olapa

80 e II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olapa

81 Olaparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that

82 ympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olap

83 First-line maintenance therapy with poly(adenosine diphosphate-ribose) polymerase inhibitors (PAR

84 The poly(adenosine diphosphate-ribose) polymerase inhibitors (PAR

85 among patients with cancer treated with poly(adenosine diphosphate-ribose) polymerase inhibitors and

86 dent kinase 4 or 6 (CDK4/6) inhibitors, poly(adenosine diphosphate-ribose) polymerase inhibitors, and

87 nstability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, com

88 cyclin-dependent kinase inhibitors and poly(adenosine diphosphate-ribose) polymerase inhibitors.

89 ospho-PKC-alpha, phospho-PKC-beta1, and poly(adenosine diphosphate-ribose) polymerase were quantified

90 actor, caspase 3, caspase 8, caspase 9, poly(adenosine diphosphate-ribose) polymerase, B-cell lymphom

91 ble, and some of these targets, such as poly(adenosine diphosphate-ribose) polymerase, Wee1, and Auro

92 -FTT) is a PET radiotracer for imaging poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1), an

93 te homolog 2 (EZH2) directly methylates poly(adenosine diphosphate-ribose) polymerase-1 (PARP-1), an

94 Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhib

95 Subsequent to the break, poly(adenosine diphosphate-ribose) polymerase-1 enzymatic act

96 activity of caspase-3/7 and cleavage of poly(adenosine diphosphate-ribose) polymerase.

97 r 1) prevents it from inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DN

98 luorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expressio

99 The poly(adenosine diphosphate-ribose)polymerase (PARP) family of

100 ed forms of caspases-2 and -3, bax, and poly-adenosine diphosphate-ribose-polymerase (PARP) by Wester

101 ATR), DNA-dependent protein kinase, and poly[adenosine diphosphate ribose] polymerase (PARP) 1/2.

102 ), enhanced cell death (caspase 3/7 and poly[adenosine diphosphate-ribose] polymerase activity, chrom

103 from targeted therapies, such as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors.

104 m the past 5 years, with an emphasis on poly[adenosine diphosphate ribose]polymerase-1 as an imaging

105 of PARPi-FL, a fluorescent inhibitor of poly[adenosine diphosphate-ribose]polymerase 1 (PARP1), which

106 Poly-adenosine diphosphate-ribose polymerases (PARPs) promote

107 an essential substrate for sirtuins and poly(adenosine diphosphate-ribose) polymerases (PARPs), which

108 Tankyrases are multifunctional poly(adenosine diphosphate-ribose) polymerases that regulate

109 other enzymes such as the sirtuins and poly(adenosine diphosphate-ribose) polymerases.

110 infection through the synthesis of a cyclic adenosine diphosphate ribose signalling molecule, which

111 Poly(ADP-ribose) (PAR) is a homopolymer of adenosine diphosphate ribose that is added to proteins a

112 entification of an unexpected molecule, poly(adenosine diphosphate ribose), that may be implicated in